Fujian Haixi Pharmaceuticals Co (HKSE:02637) Total Receivables: HK$59.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02637 Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
23 GF Score
Price HK$204.80
! 2 Warning Signs
View Full Analysis

What is Fujian Haixi Pharmaceuticals Co Total Receivables?

Fujian Haixi Pharmaceuticals Co HKSE:02637 +3.28% 23 Total Receivables is HK$59.6 Mil as of Dec. 2025. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Fujian Haixi Pharmaceuticals Co's Total Receivables for the quarter that ended in Dec. 2025 was HK$59.6 Mil.

Fujian Haixi Pharmaceuticals Co Total Receivables Related Terms

Fujian Haixi Pharmaceuticals Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Fujian Haixi Pharmaceuticals Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fujian Haixi Pharmaceuticals Co Total Receivables Chart

Fujian Haixi Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Receivables
10.76 37.66 40.24 59.57

Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
Total Receivables 10.76 37.66 40.24 59.57
HKSE:02637
23GF Score
Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fujian Haixi Pharmaceuticals Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$59.6 Mil mean?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a Total Receivables of HK$59.6 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors.
Is Fujian Haixi Pharmaceuticals Co's Total Receivables too high?
Fujian Haixi Pharmaceuticals Co's current Total Receivables is HK$59.6 Mil. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's Total Receivables compare to ZTS?
Fujian Haixi Pharmaceuticals Co's Total Receivables of HK$59.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. Fujian Haixi Pharmaceuticals Co's current Total Receivables is HK$59.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current Total Receivables of HK$59.6 Mil. The current Total Receivables is HK$59.6 Mil. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current Total Receivables is HK$59.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fujian Haixi Pharmaceuticals Co Business Description

Address No. 177 Jinda Road, Floor 3rd & 4th, Block B, Jianxin Town, Cangshan District,Fujian Province, Fuzhou, CHN, 350028
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score

Get the complete analysis for HKSE:02637

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$204.80
Price